Search, bioprospecting and biodiversity conservation

被引:17
作者
Costello, Christopher
Ward, Michael
机构
[1] Univ Calif Santa Barbara, Donald Bren Sch Environm Sci & Management, Santa Barbara, CA 93106 USA
[2] Univ Calif Santa Barbara, Dept Econ, Santa Barbara, CA 93106 USA
[3] Australian Natl Univ, Crawford Sch Econ & Govt, Canberra, ACT, Australia
关键词
bioprospecting; biodiversity; conservation; efficient search; information;
D O I
10.1016/j.jeem.2006.04.001
中图分类号
F [经济];
学科分类号
02 ;
摘要
To what extent can private-sector bioprospecting incentives be relied upon for the protection of biological diversity? The literature contains dramatically different estimates of these incentives, from trivial to quite large. We resolve this controversy by isolating the fundamental source of the discrepancy and then providing empirically defensible estimates based on that analysis. Results demonstrate that the bioprospecting incentive is unlikely to generate much private-sector conservation. Thus, other mechanisms are likely required to preserve the public good of biodiversity. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:615 / 626
页数:12
相关论文
共 29 条
[1]   The role of natural product chemistry in drug discovery [J].
Butler, MS .
JOURNAL OF NATURAL PRODUCTS, 2004, 67 (12) :2141-2153
[2]  
Cronquist A., 1981, INTEGRATED SYSTEM CL
[3]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[4]   COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].
DIMASI, JA ;
HANSEN, RW ;
GRABOWSKI, HG ;
LASAGNA, L .
JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142
[5]   The value of plants used in traditional medicine for drug discovery [J].
Fabricant, DS ;
Farnsworth, NR .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2001, 109 :69-75
[6]   POTENTIAL CONSEQUENCE OF PLANT EXTINCTION IN THE UNITED-STATES ON THE CURRENT AND FUTURE AVAILABILITY OF PRESCRIPTION DRUGS [J].
FARNSWORTH, NR ;
SOEJARTO, DD .
ECONOMIC BOTANY, 1985, 39 (03) :231-240
[7]   Bioprospecting - why is it so unrewarding? [J].
Firn, RD .
BIODIVERSITY AND CONSERVATION, 2003, 12 (02) :207-216
[8]   RETURNS TO RESEARCH-AND-DEVELOPMENT ON NEW DRUG INTRODUCTIONS IN THE 1980S [J].
GRABOWSKI, HG ;
VERNON, JM .
JOURNAL OF HEALTH ECONOMICS, 1994, 13 (04) :383-406
[9]   The distribution of sales revenues from pharmaceutical innovation [J].
Grabowski, HG ;
Vernon, J .
PHARMACOECONOMICS, 2000, 18 (Suppl 1) :21-32
[10]   Species preservation and biodiversity value: a real options approach [J].
Kassar, I ;
Lasserre, P .
JOURNAL OF ENVIRONMENTAL ECONOMICS AND MANAGEMENT, 2004, 48 (02) :857-879